First it was de prioritised on the basis that the trial had run...

First it was de prioritised on the basis that the trial had run its course and partners were being sought for ph3 and the discussions were around a transaction of some kind. At a guess there was a gap between what Imugene thought it was worth and what was being offered.
Now it’s off the slide decks for now and the company is single minded like attacking the prized assets in Oasis, Mast trials and Azer cel - so much amazing possibilities in that lot to keep even the doubters glued. I’m loving this to bits.
I’m not necessarily disagreeing with you and really trying to see strategically what might be going on. Let’s also not discount further updates later in the year that might blindside a few preconceptions.